XML 70 R53.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Collaborative Arrangements - Narrative (Details) $ in Thousands | 1 Months Ended | 3 Months Ended | 12 Months Ended |  |  |  |
--- | --- | --- | --- | --- | --- | --- | ---
Jan. 31, 2024 USD ($) | Aug. 31, 2022 USD ($) | Jul. 31, 2022 USD ($) shares | Dec. 31, 2021 USD ($) shares | Jun. 30, 2020 USD ($) shares | Dec. 31, 2019 USD ($) | May 31, 2019 USD ($) | Dec. 31, 2015 | Feb. 29, 2012 | Jun. 30, 2023 USD ($) | Sep. 30, 2022 shares | Dec. 31, 2024 USD ($) payment shares | Dec. 31, 2023 USD ($) payment shares | Dec. 31, 2022 USD ($) payment shares | Mar. 31, 2023 USD ($) | Dec. 31, 2020 USD ($) | Oct. 31, 2020 USD ($) | Mar. 31, 2020 USD ($) plan
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Performance obligations satisfied |  |  |  |  |  |  |  |  |  |  |  | $ 10,121 | $ 17,937 |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  | 59,345 | 70,143 | $ 138,590 |  |  |  |
Contract liabilities: deferred revenue |  |  |  |  |  |  |  |  |  |  |  | 450 | 10,761 |  |  |  |  |
Investments in non-marketable securities |  |  |  |  |  |  |  |  |  |  |  | 0 | 1,191 | 5,300 |  |  |  |
Milestone Payment Per Target Gene |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent receivable |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 104,000
Product revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  | 36,786 | 42,906 | 116,676 |  |  |  |
Product revenue | Related Party |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  | $ 0 | $ 0 | $ 514 |  |  |  |
Sitagliptin Enzyme | Revenue Benchmark | Collaborative Arrangement Concentration Risk |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Concentration risk, percentage |  |  |  |  |  |  |  |  |  |  |  | 12.00% | 6.00% | 4.00% |  |  |  |
Research and development revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  | $ 22,559 | $ 27,237 | $ 21,914 |  |  |  |
Research and development revenue | Related Party |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1,245 |  |  |  |
Supply Agreement | Product revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contract liabilities: deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  | 1,300 |  |  |  |  |
Enzyme Supply Agreement | Product revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  | 3,200 |  |  |  |  |
Merck | Sitagliptin Enzyme |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  | 2,500 |  |  |  |  |  |
Merck | Supply Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Term of collaborative research and development agreement |  |  |  |  |  |  |  | 5 years | 5 years |  |  |  |  |  |  |  |  |
Merck | Supply Agreement | Product revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Performance obligations satisfied |  |  |  |  |  |  |  |  |  |  |  | 7,100 | 4,400 | 5,900 |  |  |  |
Nestec Ltd. (Nestle Health Sciences) | Strategic Collaboration Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  | 0 | 4,100 | 7,100 |  |  |  |
Nestlé Health Science | Acquisition Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  | 5,000 |  |  |  |  |
Collaborative arrangement, upfront fee amount | $ 5,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Novartis |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Performance obligations satisfied |  |  |  |  |  |  |  |  |  |  |  | 1,000 | 1,100 | 1,000 |  |  |  |
Contract liabilities: deferred revenue |  |  |  |  |  |  | $ 5,000 |  |  |  |  |  |  |  |  |  |  |
Novartis | Milestone One |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent receivable |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 4,000 |  |
Novartis | Milestone Two |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent receivable |  |  |  | $ 5,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Novartis | Computer equipment and software |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent annual payments, term |  |  |  |  |  |  | 4 years |  |  |  |  |  |  |  |  |  |  |
Contingent annual receivable increase |  |  |  |  |  |  | $ 8,000 |  |  |  |  |  |  |  |  |  |  |
Revenue recognition, annual payment |  |  |  |  |  |  |  |  |  |  |  | $ 6,000 | $ 6,000 | $ 6,000 |  |  |  |
Revenue recognition, number of annual payment | payment |  |  |  |  |  |  |  |  |  |  |  | 3 | 3 | 3 |  |  |  |
Roche | Milestone One |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contract liabilities: deferred revenue |  |  |  |  |  | $ 800 |  |  |  |  |  |  |  |  |  |  |  |
Number of days for payment |  |  |  |  |  | 45 days |  |  |  |  |  |  |  |  |  |  |  |
Roche | Milestone Two |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent receivable |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 900 |
Roche | Research and development revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  | $ 6,000 |  |  |  |  |  |
Takeda |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contract liabilities: deferred revenue |  |  |  |  |  |  |  |  |  |  |  | 0 | $ 0 |  |  |  |  |
Number of program plans | plan |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3
Revenue recognized, including opening balance |  |  |  |  |  |  |  |  |  |  |  | 800 | 2,000 | $ 4,900 |  |  |  |
Takeda | Up-front Payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contract liabilities: deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 8,500
MAI | Commercialization And Enzyme Supply Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate commercial sales, milestone |  |  |  |  | $ 5,000 |  |  |  |  |  |  |  |  |  |  |  |  |
MAI | Master Collaboration & Research Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized from transactions |  |  |  |  |  |  |  |  |  |  |  | $ 0 | $ 0 | $ 1,200 |  |  |  |
MAI | Series A Preferred Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Investment owned, balance (in shares) | shares |  |  |  |  | 1,587,050 |  |  |  |  |  |  |  |  |  |  |  |  |
Investments in non-marketable securities |  |  |  |  | $ 1,000 |  |  |  |  |  |  |  |  |  |  |  |  |
MAI | Series B Preferred Stock | Related Party |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments received (in shares) | shares |  |  | 1,587,049 | 1,587,049 |  |  |  |  |  |  | 1,587,049 |  |  |  |  |  |  |
MAI | Series A and B Preferred Stock | Master Collaboration & Research Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Investment owned, balance (in shares) | shares |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1,587,049 |  |  |  |
MAI | Product revenue | Master Collaboration & Research Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized from transactions |  |  |  |  |  |  |  |  |  |  |  | $ 200 | $ 200 | $ 500 |  |  |  |
MAI | Revenue sharing arrangement | Commercialization And Enzyme Supply Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contract liabilities: deferred revenue |  |  |  |  | $ 500 |  |  |  |  |  |  |  |  |  |  |  |  |
MAI | Revenue sharing arrangement | Master Collaboration & Research Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized from transactions |  |  |  |  |  |  |  |  |  |  |  | 100 |  |  |  |  |  |
MAI Agreement | Related Party |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
MAI agreement milestone payment received |  |  | $ 1,000 | $ 1,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Pfizer | Research and development revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  | $ 5,000 |  | 9,500 | 2,000 |  |  |  |  |
Pfizer | Enzyme Product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Performance obligations satisfied |  |  |  |  |  |  |  |  |  |  |  |  | 8,200 | $ 75,400 |  |  |  |
Contract liabilities: deferred revenue |  |  |  |  |  |  |  |  |  |  |  | 0 | 9,500 |  |  |  |  |
Contract with customer, liability, retainer fee |  | $ 25,900 |  |  |  |  |  |  |  |  |  | $ 25,900 | $ 25,900 |  |  |  |  |
Contract with customer, liability, retainer fee, creditable percentage |  | 90.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contract with customer, liability, portion of retainer fee |  | $ 23,300 |  |  |  |  |  |  |  |  |  |  |  |  | $ 23,300 |  |  |
Contract with customer, liability, retainer fee, non-creditable percentage |  |  |  |  |  |  |  |  |  |  |  | 50.00% |  |  |  |  |  |
Pfizer | Enzyme Product | Revenue from Contract with Customer Benchmark | Customer Concentration Risk |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Concentration risk, percentage |  |  |  |  |  |  |  |  |  |  |  | 0.00% | 12.00% | 54.00% |  |  |  |

X
- Definition Collaborative Arrangement, Upfront Fee Amount + References No definition available. + Details
Name: | cdxs_CollaborativeArrangementUpfrontFeeAmount
Namespace Prefix: | cdxs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Contract With Customer, Liability, Portion Of Retainer Fee + References No definition available. + Details
Name: | cdxs_ContractWithCustomerLiabilityPortionOfRetainerFee
Namespace Prefix: | cdxs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contract With Customer, Liability, Retainer Fee + References No definition available. + Details
Name: | cdxs_ContractWithCustomerLiabilityRetainerFee
Namespace Prefix: | cdxs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contract With Customer, Liability, Retainer Fee, Creditable Percentage + References No definition available. + Details
Name: | cdxs_ContractWithCustomerLiabilityRetainerFeeCreditablePercentage
Namespace Prefix: | cdxs_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contract With Customer, Liability, Retainer Fee, Non-Creditable Percentage + References No definition available. + Details
Name: | cdxs_ContractWithCustomerLiabilityRetainerFeeNonCreditablePercentage
Namespace Prefix: | cdxs_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contract with Customer, Liability, Revenue Recognized, Including Opening Balance + References No definition available. + Details
Name: | cdxs_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance
Namespace Prefix: | cdxs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Contract With Customer, Sales Milestone + References No definition available. + Details
Name: | cdxs_ContractWithCustomerSalesMilestone
Namespace Prefix: | cdxs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Equity Securities Without Readily Determinable Fair Value, Shares, Milestone Payments Received + References No definition available. + Details
Name: | cdxs_EquitySecuritiesWithoutReadilyDeterminableFairValueSharesMilestonePaymentsReceived
Namespace Prefix: | cdxs_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Program Plans + References No definition available. + Details
Name: | cdxs_NumberOfProgramPlans
Namespace Prefix: | cdxs_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Related Party Transaction, Milestone Payment Received + References No definition available. + Details
Name: | cdxs_RelatedPartyTransactionMilestonePaymentReceived
Namespace Prefix: | cdxs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue Recognition, Annual Payment + References No definition available. + Details
Name: | cdxs_RevenueRecognitionAnnualPayment
Namespace Prefix: | cdxs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Revenue Recognition, Contingent Annual Payments, Term + References No definition available. + Details
Name: | cdxs_RevenueRecognitionContingentAnnualPaymentsTerm
Namespace Prefix: | cdxs_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue Recognition, Contingent Annual Receivable Increase + References No definition available. + Details
Name: | cdxs_RevenueRecognitionContingentAnnualReceivableIncrease
Namespace Prefix: | cdxs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Revenue Recognition, Contingent Receivable + References No definition available. + Details
Name: | cdxs_RevenueRecognitionContingentReceivable
Namespace Prefix: | cdxs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Revenue Recognition, Milestone Revenue, Number Of Days For Payment + References No definition available. + Details
Name: | cdxs_RevenueRecognitionMilestoneRevenueNumberOfDaysForPayment
Namespace Prefix: | cdxs_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue Recognition, Number Of Annual Payment + References No definition available. + Details
Name: | cdxs_RevenueRecognitionNumberOfAnnualPayment
Namespace Prefix: | cdxs_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Term of collaborative research and development agreement. + References No definition available. + Details
Name: | cdxs_TermOfCollaborativeResearchAndDevelopmentAgreement
Namespace Prefix: | cdxs_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of shares of investment owned. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 + Details
Name: | us-gaap_InvestmentOwnedBalanceShares
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of gross operating revenue recognized in a nonmonetary transaction. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 845 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482864/845-10-50-1 + Details
Name: | us-gaap_NonmonetaryTransactionGrossOperatingRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of cash outflow to acquire investments classified as other. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireOtherInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cdxs_MilestonePaymentPerTargetGeneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=cdxs_SitagliptinEnzymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=cdxs_CollaborativeArrangementConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=cdxs_ResearchandDevelopmentRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=cdxs_SupplyAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=cdxs_EnzymeSupplyAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cdxs_MerckMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cdxs_NestecLtd.NestleHealthSciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=cdxs_StrategicCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cdxs_NestleHealthScienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=cdxs_AcquisitionAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cdxs_NovartisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cdxs_MilestoneOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cdxs_MilestoneTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=cdxs_ComputerEquipmentAndSoftwareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cdxs_RocheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cdxs_TakedaPharmaceuticalCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cdxs_UpFrontPaymentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cdxs_MolecularAssembliesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=cdxs_CommercializationAndEnzymeSupplyAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=cdxs_MasterCollaborationResearchAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=cdxs_SeriesAAndBPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_RoyaltyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cdxs_MAIAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cdxs_PfizerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=cdxs_EnzymeProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |